Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma

Basit Öğe Kaydı
dc.authorwosidUygun, Kazim/AFL-7917-2022
dc.authorwosidküçücük, seden/JWP-5854-2024
dc.authorwosidAydiner, Adnan/AAU-4591-2020
dc.authorwosidSaip, pınar/AAT-1500-2020
dc.authorwosidUygun, Kazim/AAG-7880-2022
dc.contributor.authorKaragol, Hakan
dc.contributor.authorSaip, Pinar
dc.contributor.authorUygun, Kazim
dc.contributor.authorKucucuk, Seden
dc.contributor.authorAydiner, Adnan
dc.contributor.authorTopuz, Erkan
dc.date.accessioned2024-06-12T11:00:24Z
dc.date.available2024-06-12T11:00:24Z
dc.date.issued2006
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Prognostic factors related to survival in patients with inoperable metastatic or recurrent endometrial carcinoma (MREC) have remained unclear due to lack of clinical trials.The management of these patients is also controversial.This study was performed to compare the efficacy and toxicity profiles of two different systemic therapies (chemotherapy vs hormonal therapy) given for the treatment of patients with MREC and to identify the impact of various prognostic factors on the survival. Methods: Between 1992 and 2004, 44 patients with MREC were admitted to our oncology department. Four cases were excluded from this retrospective study because of lack of data in their charts. Age, presence of other systemic diseases (such as diabetes mellitus, hypertension), histological type, tumor grade, staae, disease-free interval, site of recurrence or metastasis, systemic treatment modality, overall response to treatment, and duration of time to progression were evaluated as prognostic factors. Cox regression analysis was per-formed for identification of independent prognostic factors and differences between patients characteristics of two treatment groups were calculated by the chi-square or t test. Results: The median follow-up was 18 mo (range 3-113). The overall response rates for chemotherapy and hormonal therapy group were 42% and 41 %, respectively (p > 0.05). The median time to progression was 4 mo for the chemotherapy group and 5 mo for the hormonal therapy group (p > 0.05). The median survival after metastasis or recurrence was I I mo for the chemotherapy group and 16 mo for the hormonal therapy group (p > 0.05). In the group of chemotherapy, grade 3-4 hematologic and northematologic toxicities were seen in eight and two, patients, respectively. No grade 3-4 toxicities were noted in patients treated with hormonal C therapy. In multivariate analysis, only time to progression (p = 0.001) and grade (p = 0.04) were the independent prognostic factors on survival after metastasis or recurrence. Conclusion: Histological differentiation and duration of time to progression are predictive factors for survival after metastasis or recurrence in the whole group. The efficacy of two different groups of treatment in these patients appears to be similar. But the chemotherapy may have some disadvantageous in terms of toxicity. This study supports a future randomized prospective trial of hormonal therapy vs chemotherapy in patients with MREC.en_US
dc.identifier.doi10.1385/MO:23:4:543
dc.identifier.endpage548en_US
dc.identifier.issn1357-0560
dc.identifier.issue4en_US
dc.identifier.pmid17303913en_US
dc.identifier.scopus2-s2.0-33846996848en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage543en_US
dc.identifier.urihttps://doi.org/10.1385/MO:23:4:543
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20811
dc.identifier.volume23en_US
dc.identifier.wosWOS:000243165600013en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHumana Press Incen_US
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometrial Carcinomaen_US
dc.subjectMetastasis Or Recurrenceen_US
dc.subjectPrognostic Factorsen_US
dc.subjectSystemic Treatmenten_US
dc.subjectGynecologic-Oncology-Groupen_US
dc.subjectPhase-Ii Trialen_US
dc.subjectCanceren_US
dc.subjectChemotherapyen_US
dc.titleEvaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu